This preview invites you into a research feature about an experimental RNA-targeting CRISPR strategy that aims to sensitize immune-cold prostate tumors to immunotherapy.
Key Takeaways
- RNA-targeting CRISPR Cas13 system was used to lengthen shortened SPSB1 mRNA in prostate cancer cells
- Restoring SPSB1 mRNA length reduced SPSB1 protein and rescued MHC-I presentation on tumor cells
- Combining this mRNA engineering with immune checkpoint therapy dramatically improved anti-tumor responses in mice